Afatinib free base

Afatinib maleate is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antitumor activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds and inhibits EGFR-1 and HER2, thereby potentially inhibiting tumor growth and angiogenesis.
Supplier Alfa Cytology
Product # BC0595
Pricing 100.0 mg, 200.0 mg, 500.0 mg, 1.0 g, 2.0 g, 5.0 g, inquire
Feedback